Connect Biopharma Expands Executive Leadership Team with Hire of Chief Financial Officer
November 22 2021 - 8:00AM
Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect
Biopharma" or the “Company”), a global clinical-stage
biopharmaceutical company dedicated to improving the lives of
patients with chronic inflammatory diseases through the development
of therapies derived from T cell-driven research, today announced
the appointment of Mr. Steven Chan as Chief Financial Officer,
effective November 22, 2021. Mr. Chan will report to Dr. Zheng Wei,
Co-Founder & CEO, and succeed Eric Hall who served as Interim
Chief Financial Officer.
“We are delighted to welcome Steven to Connect’s
Executive team at this exciting time for the Company. Steven brings
over 25 years of financial leadership and expertise across multiple
different industry sectors, including healthcare, biotechnology,
financial services, consumer products and manufacturing, and in
private, private-to-public transition and commercial stage
companies that will be of significant benefit to the continued
delivery of Connect’s strategic objectives. We would also like to
thank Eric for his significant contribution in the past several
months as we transitioned into a publicly traded company,” said Dr.
Zheng Wei.
Mr. Chan joins Connect from Delphon Industries
LLC, a global materials manufacturer for the semiconductor,
photonics, electronics and medical industries based in Hayward,
California where he served as Chief Financial Officer and led its
finance, human resources and legal functions. Prior to Delphon
Industries, Mr. Chan served as head of finance and principal
financial and accounting officer at Arcus Biosciences, a publicly
traded oncology focused biotechnology company where he helped lead
its IPO and subsequent public company infrastructure build-out. Mr.
Chan has also held financial leadership positions at several listed
companies in the technology, financial services, and life sciences
sectors, including Myokardia, Inc., Solta Medical Inc., Moody’s
Analytics, and Logitech, Inc. He received his B.S. in Business
Administration from the Haas School of Business at the University
of California, Berkeley and is a Certified Public Accountant in
California (inactive).
“I am delighted to be joining Connect to lead
their finance function and see great opportunities for the
Company’s continued development following their recent IPO and the
significant progress achieved with their innovative pipeline,” said
Mr. Chan.
About Connect Biopharma Holdings
LimitedConnect Biopharma Holdings Limited is a global
clinical-stage biopharmaceutical company dedicated to improving the
lives of patients living with chronic inflammatory diseases through
the development of therapies derived from our T cell-driven
research.
Our lead product candidate, CBP-201, an antibody
designed to target interleukin-4 receptor alpha (IL-4Rα), has been
in clinical trials for the treatment of atopic dermatitis (AD),
asthma, and chronic rhinosinusitis with nasal polyps (CRSwNP). Our
second lead product candidate, CBP-307, a modulator of a T cell
receptor known as sphingosine 1-phosphate receptor 1 (S1P1), has
been in clinical trials for the treatment of ulcerative colitis
(UC) and Crohn’s disease (CD). Furthermore, we have started the
clinical development of an additional product candidate, CBP-174, a
peripherally acting antagonist of histamine receptor 3, for the
treatment of pruritus associated with AD.
With headquarters in China, additional
operations in the United States and Australia, and clinical
development activities in those geographies as well as Europe,
Connect Biopharma is building a rich global pipeline of internally
designed, wholly owned small molecules and antibodies targeting
several aspects of T cell biology. For additional information about
Connect Biopharma, please visit our website at
www.connectbiopharm.com.
FORWARD-LOOKING STATEMENTS
Connect Biopharma cautions that statements
included in this press release that are not a description of
historical facts are forward-looking statements. Words such as
"may," "could," "will," "would," "should," "expect," "plan,"
"anticipate," "believe," "estimate," "intend," "predict," "seek,"
"contemplate," "potential," "continue" or "project" or the negative
of these terms or other comparable terminology are intended to
identify forward-looking statements. The inclusion of
forward-looking statements shall not be regarded as a
representation by Connect Biopharma that any of its plans will be
achieved. Actual results may differ from those set forth in this
release due to the risks and uncertainties inherent in the Connect
Biopharma business and other risks described in the Company's
filings with the Securities and Exchange Commission (“SEC”).
Investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof,
and Connect Biopharma undertakes no obligation to revise or update
this news release to reflect events or circumstances after the date
hereof. Further information regarding these and other risks is
included in Connect Biopharma's filings with the SEC which are
available from the SEC’s website (www.sec.gov) and on Connect
Biopharma’s website (www.connectbiopharm.com) under the heading
"Investors." All forward-looking statements are qualified in their
entirety by this cautionary statement. This caution is made under
the safe harbor provisions of Section 21E of the Private Securities
Litigation Reform Act of 1995.
IR/PR Contacts: Lazar FINN Partners David
Carey (IR) T: +1-(212)
867-1768david.carey@finnpartners.comErich Sandoval
(Media)T:
+1-(917)-497-2867erich.sandoval@finnpartners.com
Corporate
Contacts:info@connectpharm.com
Connect Biopharma (NASDAQ:CNTB)
Historical Stock Chart
From Apr 2024 to May 2024
Connect Biopharma (NASDAQ:CNTB)
Historical Stock Chart
From May 2023 to May 2024